Zacks Investment Research upgraded shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) from a sell rating to a hold rating in a research note published on Tuesday.

According to Zacks, “Edge Therapeutics, Inc. is a biotechnology company which discovers, develops and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate which are in preclinical trial EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage, EG-1964, to prevent recurrent bleeding after treatment for cSDH and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. is headquartered in Berkeley Heights, New Jersey. “

Separately, BidaskClub raised shares of Edge Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 3rd.

Edge Therapeutics (NASDAQ EDGE) opened at 10.55 on Tuesday. The stock has a 50 day moving average price of $10.60 and a 200 day moving average price of $9.88. Edge Therapeutics has a one year low of $7.30 and a one year high of $13.50. The company’s market cap is $325.48 million.

Edge Therapeutics (NASDAQ:EDGE) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). On average, equities analysts anticipate that Edge Therapeutics will post ($1.87) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Edge Therapeutics, Inc. (EDGE) Lifted to “Hold” at Zacks Investment Research” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/edge-therapeutics-inc-edge-lifted-to-hold-at-zacks-investment-research/1536013.html.

In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the company’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $10.19, for a total value of $76,425.00. Following the completion of the sale, the insider now directly owns 132,736 shares of the company’s stock, valued at approximately $1,352,579.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Albert N. Marchio II sold 2,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $10.42, for a total transaction of $26,050.00. Following the completion of the sale, the insider now directly owns 3,361 shares of the company’s stock, valued at $35,021.62. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,500 shares of company stock valued at $191,840. 36.19% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of EDGE. California State Teachers Retirement System increased its stake in shares of Edge Therapeutics by 7.7% in the second quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock worth $361,000 after buying an additional 2,500 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Edge Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock worth $186,000 after buying an additional 3,764 shares during the last quarter. State Street Corp increased its stake in shares of Edge Therapeutics by 16.3% in the second quarter. State Street Corp now owns 277,352 shares of the biotechnology company’s stock worth $2,847,000 after buying an additional 38,909 shares during the last quarter. DAFNA Capital Management LLC purchased a new stake in shares of Edge Therapeutics during the second quarter worth about $199,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Edge Therapeutics during the second quarter worth about $21,962,000. 49.38% of the stock is owned by institutional investors and hedge funds.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Get a free copy of the Zacks research report on Edge Therapeutics (EDGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.